Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

Core Insights - Biodesix, Inc. reported preliminary financial results for Q4 and fiscal year 2025, with estimated revenues of $28.8 million for Q4 and $88.5 million for the full year, representing increases of 41% and 24% respectively [1][2][7] Financial Performance - The company achieved a strong Q4, exceeding its revenue guidance of $84-$86 million for the full year [3] - Lung Diagnostics revenue was estimated at $25.2 million for Q4 and $79.2 million for fiscal 2025, marking increases of 47% and 22% respectively [7] - Test volumes for Lung Diagnostics reached 18,000 in Q4 and 62,600 for the full year, reflecting growth of 23% and 15% year-over-year [7] - Development Services revenue was estimated at $3.6 million for Q4 and $9.3 million for fiscal 2025, showing increases of 13% and 41% respectively [7] Cash Position - As of December 31, 2025, Biodesix reported cash and cash equivalents of $19.0 million, a 14% increase from Q3 2025, which included $2.3 million in at-the-market proceeds [7]